OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Showing 26-50 of 56 citing articles:
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 9
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 9
New Treatment Options in Metastatic Pancreatic Cancer
Marta Fudalej, Daria Kwaśniewska, Paweł Nurzyński, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2327-2327
Open Access | Times Cited: 9
Marta Fudalej, Daria Kwaśniewska, Paweł Nurzyński, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2327-2327
Open Access | Times Cited: 9
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS mutations
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy
Theodora Katopodi, Savvas Petanidis, Eirini Grigoriadou, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 455-455
Open Access | Times Cited: 3
Theodora Katopodi, Savvas Petanidis, Eirini Grigoriadou, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 455-455
Open Access | Times Cited: 3
Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Soonsil Hyun, Dongyun Shin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12142-12142
Open Access | Times Cited: 19
Soonsil Hyun, Dongyun Shin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12142-12142
Open Access | Times Cited: 19
KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics
Pankaj Kumar Tripathi, Khushi Mittal, Nandini Jain, et al.
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 3, pp. 268-279
Closed Access | Times Cited: 7
Pankaj Kumar Tripathi, Khushi Mittal, Nandini Jain, et al.
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 3, pp. 268-279
Closed Access | Times Cited: 7
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Small molecular inhibitors: Therapeutic strategies for pancreatic cancer
Yuvasri Golivi, Seema Kumari, Batoul Farran, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104053-104053
Closed Access | Times Cited: 2
Yuvasri Golivi, Seema Kumari, Batoul Farran, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104053-104053
Closed Access | Times Cited: 2
The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma
Yuting Liu, Shing Chun Tang, Chi Han Li, et al.
Cancer Science (2024) Vol. 115, Iss. 10, pp. 3288-3304
Open Access | Times Cited: 2
Yuting Liu, Shing Chun Tang, Chi Han Li, et al.
Cancer Science (2024) Vol. 115, Iss. 10, pp. 3288-3304
Open Access | Times Cited: 2
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
Karolina A. Kilowski, Martin Dietrich, Joanne Xiu, et al.
Gynecologic Oncology (2024) Vol. 191, pp. 299-306
Open Access | Times Cited: 2
Karolina A. Kilowski, Martin Dietrich, Joanne Xiu, et al.
Gynecologic Oncology (2024) Vol. 191, pp. 299-306
Open Access | Times Cited: 2
KRAS mutations promote the intratumoral colonization of enterotoxigenic bacteroides fragilis in colorectal cancer through the regulation of the miRNA3655/SURF6/IRF7/IFNβ axis
Yizhen Chen, Shaolin Liu, Song Tan, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Yizhen Chen, Shaolin Liu, Song Tan, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
Christophe Bontoux, Véronique Hofman, Patrick Brest, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1628-1628
Open Access | Times Cited: 12
Christophe Bontoux, Véronique Hofman, Patrick Brest, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1628-1628
Open Access | Times Cited: 12
Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research
Sergiu Chira, Andreea Nuțu, Ecaterina Isacescu, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2781-2781
Open Access | Times Cited: 11
Sergiu Chira, Andreea Nuțu, Ecaterina Isacescu, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2781-2781
Open Access | Times Cited: 11
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Neal S. Akhave, Amadeo B. Biter, David S. Hong
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 11, pp. 1645-1651
Open Access | Times Cited: 9
Neal S. Akhave, Amadeo B. Biter, David S. Hong
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 11, pp. 1645-1651
Open Access | Times Cited: 9
Computational design and validation of effective siRNAs to silence oncogenic KRAS
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
3 Biotech (2023) Vol. 13, Iss. 11
Open Access | Times Cited: 5
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
3 Biotech (2023) Vol. 13, Iss. 11
Open Access | Times Cited: 5
A Systems Biology Analysis of Chronic Lymphocytic Leukemia
Giulia Pozzati, Jinrui Zhou, Hananel Hazan, et al.
Onco (2024) Vol. 4, Iss. 3, pp. 163-191
Open Access | Times Cited: 1
Giulia Pozzati, Jinrui Zhou, Hananel Hazan, et al.
Onco (2024) Vol. 4, Iss. 3, pp. 163-191
Open Access | Times Cited: 1
PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes
Ioannis A. Voutsadakis
Cancer Genomics & Proteomics (2024) Vol. 21, Iss. 5, pp. 533-548
Open Access | Times Cited: 1
Ioannis A. Voutsadakis
Cancer Genomics & Proteomics (2024) Vol. 21, Iss. 5, pp. 533-548
Open Access | Times Cited: 1
Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy
Umm e Laila, Wang An, Zhi-Xiang Xu
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Umm e Laila, Wang An, Zhi-Xiang Xu
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Chunhua Wu, Wenfei Li, Mifen Chen, et al.
Holistic Integrative Oncology (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Chunhua Wu, Wenfei Li, Mifen Chen, et al.
Holistic Integrative Oncology (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 3
How Driver Oncogenes Shape and Are Shaped by Alternative Splicing Mechanisms in Tumors
Weronika Wojtyś, Magdalena Oroń
Cancers (2023) Vol. 15, Iss. 11, pp. 2918-2918
Open Access | Times Cited: 3
Weronika Wojtyś, Magdalena Oroń
Cancers (2023) Vol. 15, Iss. 11, pp. 2918-2918
Open Access | Times Cited: 3
Clinical Progress of KRAS-targeted Therapies: What next?
Misako Nagasaka, Asfar S. Azmi
Future Medicinal Chemistry (2022) Vol. 14, Iss. 15, pp. 1107-1110
Closed Access | Times Cited: 5
Misako Nagasaka, Asfar S. Azmi
Future Medicinal Chemistry (2022) Vol. 14, Iss. 15, pp. 1107-1110
Closed Access | Times Cited: 5
Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure
Alexandra Maria Psaras, Rhianna K. Carty, Jared T. Miller, et al.
Genes (2022) Vol. 13, Iss. 8, pp. 1440-1440
Open Access | Times Cited: 3
Alexandra Maria Psaras, Rhianna K. Carty, Jared T. Miller, et al.
Genes (2022) Vol. 13, Iss. 8, pp. 1440-1440
Open Access | Times Cited: 3
KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer
Abdullah Althaiban, Anita Thyagarajan, Ravi P. Sahu
Mini-Reviews in Medicinal Chemistry (2022) Vol. 23, Iss. 8, pp. 953-961
Closed Access | Times Cited: 3
Abdullah Althaiban, Anita Thyagarajan, Ravi P. Sahu
Mini-Reviews in Medicinal Chemistry (2022) Vol. 23, Iss. 8, pp. 953-961
Closed Access | Times Cited: 3
A Systems Biology Analysis of Chronic Lymphocytic Leukemia
Giulia Pozzati, Jinrui Zhou, Hananel Hazan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Giulia Pozzati, Jinrui Zhou, Hananel Hazan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Anastasia Karachaliou, Ηλίας Κοττέας, Oraianthi Fiste, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1447-1447
Open Access
Anastasia Karachaliou, Ηλίας Κοττέας, Oraianthi Fiste, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1447-1447
Open Access
